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Translational relevance: The presence of cycling hypoxia is a key 
determinant of radio-resistance, impaired drug delivery and increased 
metastatic potential in head and neck squamous cell carcinoma (HNSCC). 
Non-invasive imaging strategies to identify and assess the magnitude and 
distribution of acutely hypoxic tumor cell subpopulations in situ may provide 
prognostic and predictive biomarkers for the treatment of HNSCC. 
Quantitation of the transverse relaxation rate, R2*, using intrinsic susceptibility 
MRI can be used to serially monitor variations in levels of paramagnetic 
deoxyhemoglobin, associated with cycling hypoxia, both in HNSCC 
xenografts and patients on a clinical 3T system. Such fluctuations are 
predominantly associated with regions of impaired tumor vasculature, the 
presence of which may be linked to a poorer outcome. 
 
Abstract:  
 
Purpose: To evaluate intrinsic susceptibility (IS) MRI for the identification of 
cycling hypoxia, and the assessment of its extent and spatial distribution, in 
head and neck squamous cell carcinoma (HNSCC) xenografts and patients.  
 
Experimental Design: Quantitation of the transverse relaxation rate R2*, which 
is sensitive to paramagnetic deoxyhemoglobin, using serial IS-MRI 
acquisitions, was used to monitor temporal oscillations in levels of 
paramagnetic deoxyhemoglobin in human CALR xenografts and patients with 
HNSCC at 3T.  Autocovariance and power spectrum analysis of variations in 
R2* was performed for each imaged voxel, to assess statistical significance 
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and frequencies of cycling changes in tumor blood oxygenation. Pathological 
correlates with tumor perfusion (Hoechst 33342), hypoxia (pimonidazole) and 
vascular density (CD31) were sought in the xenografts, and dynamic contrast 
enhanced (DCE) MRI was used to assess patient tumor vascularization. The 
prevalence of fluctuations within patient tumors, DCE parameters and 
treatment outcome were reported. 
 
Results: Spontaneous R2* fluctuations with a median periodicity of 15 minutes 
were detected in both xenografts and patient tumors. Spatially these 
fluctuations were predominantly associated with regions of heterogeneous 
perfusion and hypoxia in the CALR xenografts. In patients, R2* fluctuations 
spatially correlated with regions of lymph nodes with low Ktrans values, typically 
in the vicinity of necrotic cores.  
Conclusion: Intrinsic susceptibility MRI can be used to monitor variations in 
levels of paramagnetic deoxyhemoglobin, associated with cycling hypoxia. 
The presence of such fluctuations may be linked with impaired tumor 
vasculature, the presence of which may impact treatment outcome. 
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Introduction  
 
Understanding the tumor microenvironment is essential for the delivery of 
personalized cancer treatment (1-3). Hypoxia, resulting from an imbalance 
between oxygen delivery and consumption, is an important component of the 
tumor microenvironment that influences the response to both radiotherapy 
and chemotherapy (2, 4, 5). Tumor hypoxia is a well-established cause of 
treatment resistance, and adversely affects the prognosis of head and neck 
squamous cell carcinoma (HNSCC) (6). Furthermore, targeting tumor hypoxia 
has been validated as a therapeutic strategy in HNSCC (6, 7), and its 
modification during standard radiotherapy can improve outcomes in terms of 
loco-regional control, disease-specific survival and overall survival (8).  
 
Historically, the low oxygen tension associated with tumors was considered to 
be a consequence of chronic or diffusion-limited hypoxia (9), and acute or 
perfusion-limited hypoxia (10). It is now clear that this is an oversimplification, 
and that the tumor microenvironment is highly dynamic and contains 
subpopulations of cancer cells exposed to continuously changing gradients of 
oxygen, nutrients and pH (11). These microenvironmental components can 
promote genomic instability within cancer cells, providing an overall selective 
advantage for malignant growth (12). For example, tumors may contain cells 
that have been differentially exposed to hypoxia for minutes to hours and then 
re-oxygenated (13-15). This process can recur, leading to ‘cycling’ hypoxia 
(16-18). Cycling hypoxia arises from variations in red blood cell (RBC) flux 
through the abnormal tumor vasculature (16, 18, 19). Several factors may 
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contribute to such fluctuations, including arteriolar vasomotion (20, 21), rapid 
vascular modeling (22), disorganized vascular hierarchy (23, 24) or increased 
transcapillary permeability (25).  
 
Experimental evidence suggests that hypoxia and anoxia can alter tumor cell 
cycle checkpoint control and the sensing and repair of DNA damage (12, 26, 
27). Pre-clinical studies have shown that the homologous recombination DNA 
repair pathway is suppressed by chronic hypoxia, whereas DNA damage-
associated checkpoint cell cycle arrest and non-homologous end joining are 
stimulated by acute hypoxia (12, 27). These factors lead to radio-resistance, 
decreased delivery of cytotoxics, and increased metastatic potential. 
Therefore, detecting the magnitude and distribution of acutely and chronically 
hypoxic tumor cell subpopulations may determine their prognostic and 
predictive value in HNSCC and help selection of optimal therapeutic 
strategies (2).   
 
Advances in imaging techniques can now provide a means of defining non-
invasive quantitative biomarkers to inform on biologically relevant structure-
function relationships in tumors, enabling their accurate detection, an 
understanding of their behavior, and report on response to treatment. One 
such approach, intrinsic susceptibility MRI (IS-MRI), involves quantitation of 
the transverse relaxation rate R2*, which is sensitive to the concentration of 
paramagnetic deoxyhemoglobin within the vascular compartment of tissues. 
Compared to most normal tissues, tumors typically exhibit relatively fast R2* 
values, a consequence of the high concentration of deoxygenated RBCs 
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within the typically chaotic and unstable microcirculation. However, the 
strength of the correlation between tissue R2* and oxygen partial pressure, 
measured in situ using oxygen probes, or via immunohistochemical detection 
of reduced 2-nitroimidazole adducts, has been reported to be at best 
moderate (28). This is likely due to the dependence of R2* on a number of 
physiological factors, including blood volume, hematocrit and vessel calibre 
(28-30). However, variations in these parameters can be greatly compensated 
for, and data interpretation simplified, through assessing modulation of R2* 
with, for example, hyperoxic gas challenge, or injection of vascular contrast 
agents. It is also possible to temporally monitor changes in R2* using 
continuous IS-MRI measurements, which have been exploited pre-clinically to 
non-invasively image cycling hypoxia at high spatial and temporal resolution 
in tumors propagated in mice (31-33).  
 
In this study, IS-MRI was initially used to measure spontaneous R2* 
fluctuations in mice bearing HNSCC xenografts on a clinical 3T MRI scanner, 
and pathological correlates sought. Subsequently, the preclinical IS-MRI 
methodology was translated to a clinical pilot study of patients with locally 
advanced HNSCC, also imaged at 3T. 
 
Materials and Methods 
 
Pre-clinical Imaging:  
 
Experiments were performed in compliance with Home Office licenses issued 
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under the UK Animals (Scientific Procedures) Act 1986 following local ethical 
approval, the United Kingdom National Cancer Research Institute guidelines 
for animal welfare in cancer research (34) and with the ARRIVE guidelines 
(35). Adult female athymic NCr nu/nu mice (n = 5, 7-8 weeks old, Charles 
River) were injected subcutaneously on the flank with 5x105 human CALR 
HNSCC cells, stably resistant to EGFR tyrosine kinase inhibitors. The CALR 
xenograft doubling time in vivo is approximately 4 days (36). Tumor volume 
was monitored using calipers and the formula for an ellipsoid, (π/6) × L × W × 
D, where L, W and D are the largest orthogonal dimensions of the ellipsoid. 
Tumors were imaged at volumes of ~500 mm3.  
 
MRI was performed on a 3T clinical scanner (Philips Achieva, Philips Medical 
Systems, Best, Netherlands) using a dedicated pre-clinical asymmetric high-
resolution three element receive coil (“Mouse Hotel”, Philips), enabling 
simultaneous measurements of up to three animals. Mice were anesthetized 
with a 10 ml/kg intraperitoneal injection of fentanyl citrate (0.315 mg/mL) plus 
fluanisone (10 mg/mL) (Hypnorm; Janssen Pharmaceutical Ltd, High 
Wycombe, UK), midazolam (5 mg/mL) (Hypnovel; Roche, Welwyn Garden 
City, UK), and water (1:1:2). Anesthetized mice (two per scanning session) 
were positioned with tumors immobilized at the center of the coil elements 
(Supplementary materials, Figure S1). Mouse core body temperature was 
maintained by a built-in heating system within the coil. A round-end cylinder 
phantom containing 1.5 mM gadoterate meglumine (Dotarem, Guerbet, 
Villepinte, France) in saline was positioned in the third coil element and used 
to monitor MR system stability (Supplementary materials, Figure S1). 
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Anatomical coronal and axial T2-weighted images were first obtained to 
localize the tumor. A 2D gradient echo sequence with 6 echo times (temporal 
resolution: 30s, FA = 24°, TE = 4.92 to 29.52 ms in increments of 4.92 ms, TR 
= 250 ms, FOV = 200 x 200 mm2, 3 slices, voxel size: 0.3 x 0.3 x 1.5 mm3) 
was then used to scan continuously over 50 minutes, providing 100 time 
points. The total scanning time was 65 min. 
 
Pathological Assessment of Tumor Perfusion, Vascularization and Hypoxia:  
 
The hypoxia marker pimonidazole (60 mg/kg, Hypoxyprobe, Burlington, MA) 
was administered i.p. to mice bearing CALR  xenografts 1 hour before the MRI 
scan, to allow for maximal bio-reduction in hypoxic tumor regions. Following 
MRI, Hoechst 33342 (15 mg/kg; Sigma-Aldrich, Poole, UK), a marker of 
perfused vessels, was injected via a lateral tail vein (37, 38). After 1 minute, 
tumors were rapidly excised and flash-frozen over liquid nitrogen. 
Fluorescence signals from Hoechst 33342 and reduced pimonidazole adducts 
bound with mouse monoclonal FITC-conjugated antibodies were detected on 
whole tumor 10µm thick frozen sections, cut in the same plane as for the MRI, 
using a motorized scanning stage (Prior Scientific Instruments, Cambridge, 
UK) attached to a BX51 microscope (Olympus Optical, London, UK), driven 
by image analysis software (CellP, Soft Imaging System, Münster, Germany) 
as previously described (38). Vessel density was then assessed through 
detection of CD31 on the same sections using rat anti-mouse CD31 
antibodies (BD Biosciences, Oxford, UK, 1:100) and Alexa 546-conjugated 
goat anti-rat IgG antibody (Invitrogen, 1:500). Tumor hypoxia, perfusion and 
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vessel density were quantified as previously described (38). 
 
Clinical Imaging:  
 
Ten patients with untreated, histologically proven HNSCC were scanned twice 
(24-168 hours apart) prior to initiation of treatment. Written informed consent 
was obtained from all patients, which was approved by the Institutional 
Research Review Board (CCR 3970) and the NHS Research Ethics 
Committee (REC number 13/LO/0628). MRI was performed at 3T 
(MAGNETOM Skyra, Siemens Healthcare, Erlangen, Germany) using a 20 
channel head and neck coil. Patients were aligned in a supine position with 
slight neck extension using a standard headrest and lateral cushions for 
improved stabilization. Anatomical coronal and axial T2-weighted images were 
first acquired to assess the extent of the disease and aid planning of 
functional imaging. Subsequently, a 2D gradient echo sequence with 6 echo 
times (temporal resolution: 30s, FA = 24°, TE = 4.92 to 29.52 ms in 
increments of 4.92 ms, TR = 250 ms, FOV = 240 x 240 mm2, 3 slices, voxel 
size: 0.9 x 0.9 x 2.5 mm3) was used to scan continuously for 1 hour (120 time 
points). Finally, DCE MRI was performed using an axial 3D FFE sequence 
(FA=3/18°, TE/TR=2.46/4.56 ms, FOV = 256 x 198 mm2, 24 slices, 1.5 x 1.5 x 
2.5 mm3 voxel, temporal resolution: 2.9 s) during which 0.2 mg/kg gadoterate 
meglumine was injected as a bolus. The total scanning time was 75 min. A 
blood sample was taken for a full blood count prior to each MRI scan to 
determine the hematocrit. 
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Signal processing:  
 
R2* maps were calculated for each time point using MatLab (MathWorks, 
Natick, MA), and the gradient echo image signal intensity decay was fitted on 
a voxel-wise basis to a mono-exponential model using a least-squares fit 
method (30). A non-rigid image registration (MIRT - Medical Image 
Registration Toolbox for Matlab, sum-of-squared-differences similarity 
measure (39)) was performed to correct for any motion in the clinical 
examinations. The shortest echo time (TE = 4.6 ms) images were used to 
calculate deformation matrices, which were subsequently applied to 
corresponding R2* maps (R2*(t)MOCO). The residual motion was inspected 
using cine loops and image intensity time traces S(t)MOCO generated for each 
tumor volume of interest (50 mm line profiles in two orthogonal directions). 
Corrected time series were analyzed for all volumes of interest (VOI) voxels to 
test for the presence of non-random fluctuations, using a power spectrum 
analysis. The following processing steps, previously described by Baudelet et 
al (31, 40), were performed: i) linear trend subtraction, ii) calculation of 
autocovariance functions, iii) calculation of power spectral density, iv) chi-
square test of power coefficients to test if fluctuations were different from the 
Gaussian noise. No data filtering or windowing was used. Coefficients in the 
frequency range of 0 - 0.005 Hz, characteristic for cycling hypoxia (14, 17, 20, 
31, 33), were considered significant. Higher frequency noise dominated 
coefficients were not included in the analysis. Significant non-Gaussian R2* 
fluctuations (one or more coefficient above P = 0.05 significance threshold) 
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were spatially mapped using binary maps (Figure 1). The total numbers of 
fluctuating voxels and percentage of fluctuating voxels in the imaged volume 
(fluctuating volume percentage) were determined for each VOI.  
 
DCE MRI was used to non-invasively investigate the vascularization of the 
patient tumors. Pharmacokinetic modeling was performed using MRIW (41) 
software and the extended Kety model (42) and a population-based arterial 
input function (43). The volume transfer constant between blood plasma and 
extracellular extravascular space, Ktrans (min-1), and enhancing fractions, EF, 
were calculated for each voxel (41).  
 
Volumes of interest from each CALR xenograft were manually delineated 
using in-house software developed in MatLab. Patient VOIs, including primary 
and nodal tumor sites, were manually delineated using the Pinnacle3 (Philips 
Healthcare, Best, Netherlands) treatment planning system (TPS). Voxel-
matched parameter maps were generated and exported using the TPS with 1 
x 1 x 2.5 mm voxel resolution. This allowed for spatial investigation of 
perfusion and permeability in fluctuating and non-fluctuating tumor regions. 
Mean values of R2* and Ktrans were calculated for enhancing regions of tumors 
and compared with fluctuating and non-fluctuating sub-volumes. Correlations 
between whole tumor median Ktrans, R2* VOI values and fluctuating volume 
percentage were also tested. 
 
Treatment and outcomes in the clinical cohort: 
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All patients received radical radiotherapy with concomitant chemotherapy 
(cisplatin 100 mg/m2 or carboplatin, AUC5, day 1 and 29) according to 
institutional protocols. Macroscopic and microscopic disease received 65 Gy 
or 54 Gy in 30 fractions, respectively, using intensity-modulated radiotherapy 
(IMRT) with a simultaneous integrated boost. Macroscopic disease was 
defined as the gross tumor identifiable on pre-treatment images and clinical 
examination whereas microscopic disease included nodal areas at risk of 
harboring microscopic disease dependent on the site of the primary tumor. 
Patients with evidence of persistent, progressive or relapsed disease, arising 
within 12 months of completion of treatment, were classed as non-
responders. The analysis of the clinical MRI data was blinded to the treatment 
outcome. 
 
Statistical analysis: 
 
The Shapiro-Wilk test was used to evaluate distribution normality of measured 
parameters. The chi-square test of power coefficients (frequency range: 0-
0.005 Hz) was used to assess if the fluctuations were different from the 
Gaussian noise. The paired t-test was used to compare the mean values of 
R2*, Ktrans (responders vs. non-responders, primary vs. lymph nodal tumors) 
and fluctuating volume percentage (responders vs. non-responders, 
fluctuating volume percentage in MR1 vs. MR2). Kendall’s tau (τ) was used to 
test for correlation between the mean fluctuating volume percentage, R2* and 
vascular/hypoxia parameters (Hoechst 33342, pimonidazole adduct fractions, 
Ktrans). A P value of 0.05 was chosen as the criterion for statistical significance 
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in all tests and adjusted to account for multiple correlation comparisons. 
Statistical analysis was performed using the Matlab Statistics Toolbox. 
 
 
Results 
 
Pre-clinical findings: 
 
The spatial distribution and volume percentage of spontaneous R2* 
fluctuations  
 
The range of CALR tumor volumes measured using T2-weighted images was 
0.48 – 0.94 cm3 with a median of 0.59 cm3. The median baseline R2* for the 
CALR xenografts was 32 s-1 (range: 26 – 50 s-1) with elevated values 
commonly found at the periphery of tumors (Figure 1A). Significant 
spontaneous R2* spatial variations were detected in all the CALR xenografts (n 
= 5), with an average fluctuating volume percentage of 8% (Table 1). Figure 
2B illustrates the spatial distribution of fluctuations in the xenograft cohort. 
Examples of power spectra measured for representative voxels in fluctuating 
and non-fluctuating regions of CALR xenografts, and adjacent muscle, are 
shown in Supplementary material, Figure S2. 
 
Perfusion and hypoxia in fluctuating sub-regions of CALR xenografts 
 
Composite images showing the distribution of Hoechst 33342, pimonidazole 
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adducts and CD31 for each CALR xenograft are shown in Figure 2C. Perfused 
vasculature was predominantly associated with the tumor periphery, with 
more hypoxic and/or avascular regions towards the core. The mean values of 
perfused and hypoxic fractions were 10.4% (range: 5.1 – 14.2) and 7% 
(range: 6.5 – 20.9) respectively.  
 
There was a negative trend (τ = - 0.8, P = 0.08, Supplementary materials, 
Figure S3) between median fluctuating and perfused tumor fractions. There 
was no correlation between median fluctuating volume percentage and 
chronic hypoxia, identified with pimonidazole staining (τ = - 0.2, P = 0.817). 
Significant R2* fluctuations were apparent in regions of the tumor with a 
heterogeneous distribution of hypoxic and perfused parts although absent in 
well-perfused areas (Figure 2B). There was no correlation between baseline 
R2* and pimonidazole or Hoechst 33342 staining (τ = 0.1, P = 1 and τ = 0.01, 
P = 1 respectively, Supplementary materials, Figure S3).  
 
Clinical findings:  
 
The spatial distribution and volume percentage of spontaneous R2* 
fluctuations  
 
A total of 7 primary sites and 11 lymph nodes were imaged and outlined for 
the purpose of the study. Patient and treatment characteristics are 
summarized in Table 2. The range of measured Hct was 0.283–0.459 and the 
mean value was 0.4. Images revealed high spatial heterogeneity in metastatic 
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lymph nodes (Figure 3). The median baseline R2* was 43 s-1 (range: 35 – 56 s-
1) for lymph nodes and 54 s-1 (range: 47 – 56 s-1) for primary tumors, which 
differed significantly (P < 0.01). Elevated R2* values were commonly found at 
the periphery of lymph nodes (Figure 4A). Primary sites were significantly 
affected by patient motion, while lymph nodes were fairly stationary 
(Supplementary materials, Figure S4). Three primary tumors were excluded 
from the analysis due to excessive motion that could not be compensated for. 
Significant R2* fluctuations were detected in 4 primary sites and 10 lymph 
nodes in 9/10 patients, with the fluctuating volume percentage varying 
between 0 and 23% (Table 2). Examples of nodal VOI fluctuation maps 
obtained in two MRI sessions (48 hours apart) are shown in Figure 4. 
Examples of power spectra measured for representative voxels in fluctuating 
and non-fluctuating parts of human HNSCC tumors, and adjacent muscle, are 
shown in Supplementary material, Figure S5.  
Mean values of fluctuating volume percentage measured in the two MRI visits 
did not differ statistically (P = 0.12). 
The distribution of fluctuating volume percentage in the patient cohort was 
positively skewed and not normal (P < 0.01). Most of the observed significant 
frequencies were in the low-frequency range < 0.003 Hz (< 1 cycle / 5.5 min) 
with a median frequency of 0.0011 Hz (1 cycle / 15 min).  
 
Ktrans and R2* in fluctuating and not fluctuating parts of patient tumors 
 
The median Ktrans values calculated for patient primary and nodal tumors were 
0.127 and 0.182 min-1 respectively. A rim-enhancing pattern, with no or low 
 17
contrast uptake in the center, was observed in 7/11 nodes. The mean nodal 
enhancing fraction was 0.86. There was no difference in enhancing fraction 
values between fluctuating and non-fluctuating parts of nodal tumors (P = 
0.84). Examples of fluctuation maps with corresponding Ktrans maps are 
shown in Figures 3 and 4. Non-random fluctuations were detected in areas of 
lymph nodes with low Ktrans values (Figure 3 IV, Figure 4), often in the vicinity, 
but not in the center, of cystic or necrotic nodes (Figure 3 II). Mean Ktrans 
values were lower in the fluctuating regions of nodal tumors (P < 0.01) and 
baseline R2* values did not differ (P = 0.97). There was no correlation 
between mean Ktrans or R2* and fluctuating volume percentage (τ = -0.09, P = 
0.75 and τ = 0.06, P = 0.87 respectively) in the lymph nodes (representative 
Ktrans and R2* distributions for fluctuating and non-fluctuating human HNSCC 
tumor regions are shown in Supplementary material, Figure S6).  
 
Treatment outcomes 
 
Clinical outcomes are presented in Table 2. Six out of 10 patients were 
classified as responders whilst three patients developed progressive or 
residual disease 3 months post-completion of the treatment (Pt 3, 5, 7). One 
patient had loco-regional disease relapse 9 months post-completion of the 
treatment (Pt 5). The mean lymph nodes fluctuating volume percentage, 
averaged for both visits, was 8% (range: 2 – 15%) in non-responders and 3% 
(range: 0 – 6%) in responders (Supplementary materials, Figure S7). The 
difference was borderline insignificant (P = 0.051). There was insufficient data 
for the primary tumor analysis. There was no difference in mean tumor Ktrans 
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(Pprimary = 0.19, Pnodes = 0.96) or R2* (Pprimary = 0.29, Pnodes = 0.81) values 
between responders and non-responders. 
 
 
Discussion 
 
In this study we describe the successful implementation of IS-MRI for non-
invasive imaging of cycling oxygenation changes in HNSCC, using a clinical 
3T MRI scanner. Following promising results from the pre-clinical phase, the 
methodology was translated to a clinical study. To the best of our knowledge, 
our study is the first application of serial IS-MRI methodology to detect cycling 
hypoxia in a clinical setting. 
 
Measurements of cycling hypoxia using serial IS-MRI was first introduced in a 
pre-clinical study of murine fibrosarcoma performed at 4.7T by Baudelet et al 
(31, 40). In our study spontaneous R2* fluctuations, reflecting varying blood 
flow and levels of oxygenation/hypoxia, were detected in both CALR 
xenografts and patients with HNSCC. Pre-clinically, the cycling variations 
were apparent in mixed perfused and hypoxic regions of the tumor, confirmed 
histologically using Hoechst 33342 uptake and pimonidazole adduct 
formation. In the patients, R2* fluctuations were observed within areas of 
lymph nodes exhibiting low Ktrans values, often in the vicinity, but not in the 
center, of necrotic nodes. It has previously been shown, that Ktrans values 
correlate with the level of perfusion (42). We observed lower Ktrans values in 
fluctuating parts of metastatic lymph nodes, which suggest that fluctuating 
 19
blood oxygen levels are caused by an insufficient or intermittent blood delivery 
as a result of aberrant vasculature. This observation aligns with another pre-
clinical study in which ~80% of the fluctuations were found to occur in tumor 
regions with immature vessels (44). This may underpin the negative trend 
observed between fluctuating R2* and perfused fraction in the CALR 
xenografts, and the negligible level of fluctuations detected within chronically 
hypoxic and avascular tumor areas identified by pimonidazole adduct 
formation and DCE MRI, respectively. The lack of correlation between 
pimonidazole, Ktrans and fluctuating volume percentage also indicates that 
regions exhibiting intermittent blood flow and cycling hypoxia cannot be 
detected using single contrast agent injection methods. The bio-reduction of 
pimonidazole is averaged in time post-injection and therefore not sensitive to 
acute changes of hypoxia. DCE data are acquired typically over a much 
shorter period of time (<10 min) and pharmacokinetic modeling assumes 
constant rates of perfusion and permeability in the assessed vasculature. 
Serial IS-MRI can be acquired over a longer period of time, revealing the 
presence of oxygen level fluctuations at frequencies characteristic of cycling 
hypoxia.   
 
Frequencies in the range of 0.00027 – 0.001 Hz (15 – 60 min) have been 
reported in preclinical measurements of cycling hypoxia (14, 17, 20, 31, 33). 
The median frequency of 0.0011 Hz (1 cycle / 15 min) found in our study is 
comparable to tumor R2* oscillation frequencies reported by Baudelet et al 
and Goncalves et al (0.0036 Hz and <0.001 Hz, respectively) (31, 33). 
CALR xenografts were used in this study as they emulate the high vascular 
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heterogeneity frequently found in HNSCC tumors in the clinic. It is expected 
that blood volume is higher in primary HNSCC tumors than metastatic lymph 
nodes, which for comparable level of tissue oxygenation would result in faster 
R2* rates (more paramagnetic deoxyHb/voxel)(30, 45). Similarly, in the case 
of severely hypoxic hypovascular tissues, such as those observed in CALR 
tumors, slow values of R2* would be predicted. The presence of hypoxic and 
under-perfused tumor sub-regions, characteristic of CALR tumors (37), has 
also been reported in patients with metastatic HNSCC lymph nodes (46). This 
is consistent with our findings of abundant regions of impaired perfusion and 
necrosis identified in both pre-clinical and clinical settings. In our study, the 
median fluctuating volume percentage, detected in all imaged CALR tumors, 
was 8% (range: 4 – 11%). This was comparable, but did not correlate (τ = - 
0.2, P = 0.817) with the pimonidazole fraction (7%). The incidence of cyclical 
hypoxia is more likely in tumor regions where the oxygen saturation of the 
blood entering that region is relatively low, resulting in a complex dynamic 
interplay between chronic and cyclical hypoxia (18). The levels of fluctuating 
and hypoxic fractions depend on the tumor type, presence of necrosis, 
vascular stability and oxygen consumption. The fluctuating volume 
percentage has also been shown to depend on the study methodology, with 
published estimates varying between 0% and 80% (17). 
 
Non-invasive measurement of cycling tumor hypoxia is challenging in patients 
due to the need for multiple data time points. Most of the methodologies that 
have been successfully used to study varying levels of hypoxia in pre-clinical 
studies are not applicable to clinical studies. Invasive studies of superficial 
 21
human tumors using laser Doppler flow measurement demonstrated 
significant changes in micro-regional blood flow in 54% of the regions 
monitored  over a 60 minute period (47, 48). Around 19% of the observed 
perfusion changes were reversed over a time course of 4-44 min. A modeling 
study using serial pre-treatment 18F-FMISO-PET scans in patients with 
HNSCC reported that acute hypoxia ranged from 13% to 52% (49). In our 
study, fluctuating volume percentage varied between 0 and 23%. The level of 
fluctuations was consistent between the scans: mean values of fluctuating 
volume percentage measured in two MRI visits did not differ statistically (P = 
0.12) confirming robustness of methodology and prevalence of cycling 
oxygenation changes in HNSCC tumors. Assuming the average patient value 
of systemic hematocrit (0.4) as the value of microvascular hematocrit, and a 
hypoxic range of blood oxygenation between 0 and 0.3, the maximum 
observed ΔR2* (~40 s-1) would correspond to a 0.2 change in blood 
oxygenation at 3T (45). This would equate to a change of between 0 and 16 
mmHg (human blood, coefficient for blood oxygen binding: 2.26, temperature: 
37ºC, pH: 7.4). 
Intriguingly, the difference of the mean fluctuating volume percentage 
between responding and non-responding patient groups approached 
statistical significance (P = 0.051), indicating the potential of R2* fluctuating 
volume percentage as a predictive and prognostic biomarker in HNSCC. This 
warrants further evaluation in a larger patient group. 
Several limitations of this study should be considered. Patient HNSCC 
primary tumor sites (e.g. base of tongue, pharynx) were affected by significant 
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internal motion that could not be compensated for and hence led to exclusion 
from the analysis. One possible way to reduce this issue would be to use 
customised oral stents (50). This may decrease patient comfort however and 
the tolerability would have to be assessed. Another limitation is the restricted 
coverage of the serial multiple gradient echo at the required temporal 
resolution. This limited our analysis to the centre part of primary tumors and 
co-planar local lymph nodes. Echo planar imaging (EPI) readouts, commonly 
used in serial IS-MRI studies of brain activity, may improve this aspect (51). 
These sequences are however prone to distortion artifacts in the vicinity of air 
and tissue interfaces, which is likely to affect HNSCC primary tumor analysis 
(52). Lastly, the prevalence and spatial distribution of oxygen fluctuation in 
patients was correlated to the transfer constant Ktrans estimated using DCE 
MRI, but not to the absolute level of chronic hypoxia, which is a common and 
well-recognized cause of radioresistance in HNSCC. MRI-based methods to 
identify chronic hypoxia employing hyperoxic challenge-induced changes in 
R2* and R1 have recently been proposed (53-55) and could be combined with 
serial IS-MRI in future studies to provide information on the impact of both 
cycling and chronic hypoxia on patient treatment.   
 
In conclusion, we demonstrated the feasibility of oxygen fluctuation mapping 
in HNSCC xenografts and translation to patient tumors using a clinical 3T MRI 
system. Our results suggest the presence of fluctuating blood oxygen levels in 
regions of impaired vasculature, but not in necrotic avascular parts of the 
tumor.  
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Figure Captions: 
 
Figure 1 A: Representative parametric R2* map (range: 0 – 100 s-1, axial 
orientation) calculated for a CALR HNSCC xenograft, with the tumor ROI 
delineated in blue. R2* time series (B, C) were used to calculate 
corresponding power spectra (E, F) and tested for the presence of non-
random fluctuations. Significant non-Gaussian R2* fluctuations (white voxels in 
binary maps D), in the frequency range of 0-0.005 Hz were spatially mapped (chi-
square test: at least one coefficient above P = 0.05, B – D).  
 
Figure 2 T2-weighted axial MRI images (A) and corresponding binary maps 
showing the spatial distribution of spontaneous non-Gaussian R2* fluctuations 
(B) within tumor ROI’s (white voxels) for CALR HNSCC xenografts (central 
slices). C: Composite images of the corresponding tumor sections showing 
the distribution of Hoechst 33342 (perfusion, blue), pimonidazole adducts 
(hypoxia, green) and CD31 (endothelial cell expression, red). 
 
Figure 3 Examples of T2-weighted axial MRI images of HNSCC patients (A). 
Distribution of spontaneous R2* fluctuations (B) within tumor ROI’s (white 
voxels) is presented for a primary tumor site (I, Pt No: 1), necrotic node (II, Pt 
No: 2) uniformly and non-uniformly contrast enhancing nodes (III, Pt No: 8 
and IV, Pt No: 7). C: Corresponding DCE maps showing distribution of volume 
transfer constant between blood plasma and extracellular extravascular space 
(Ktrans).  
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Figure 4 MRI parametric maps for a stage IV HNSCC patient with a zoomed 
nodal ROI region. Transverse relaxation rate R2* (A), Ktrans (B) and binary 
maps (C: MR1, D: MR2, two MR sessions 48 hours apart) showing spatial 
distribution of spontaneous non-Gaussian R2* fluctuations (white voxels) for a 
nodal ROI (Patient No 5, N2). 
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Table 1 Summary of CALR Tumour Characteristics 
Mouse No. 
Tumour 
volume 
[cc] 
H33342 
fraction 
[%] 
Pimonidazole 
fraction 
[%] 
R2* 
 
[s-1] 
Fluctuating 
volume 
[%] 
1 0.41 14 7 32 4 
2 0.48 10 17 50 10 
3 0.94 13 21 26 7 
4 0.59 5 2 27 11 
5 0.92 8 7 34 8 
Median 0.59 10 7 32 8 
 
 
 
Table 2. Summary of Patient Tumour Characteristics 
 “-”: no primary / lymph node in the imaged volume, “NA”: data not available due to extensive motion, “R/NR” – responder / non-
responder; 
 
                           Primary Tumours Lymph Nodes  
Pt 
Primary 
site 
P vol 
[cc] 
R2* 
[s-1] 
Ktrans 
[min-1] 
MR1 
Fluct. 
Vol. 
[%] 
MR2  
Fluct. 
Vol. 
[%] 
LN 
vol 
[cc] 
R2* 
[s-1] 
Ktrans 
[min-1] 
MR1 
Fluct. 
Vol. 
[%] 
MR2 
Fluct. 
Vol. 
[%] Outcome 
1 Oropharynx 12 50 0.153 1 4 15 52 0.264 1 1 R 
2 51 0.186 2 10  
2 Oropharynx 32 54 0.079 NA NA 3 38 0.046 0 0 R 
3 Supraglottis 27 54 0.135 NA NA 2 42 0.277 4 6 NR 
4 Oropharynx 29 47 0.112 2 1 - - - - - R 
5 Oropharynx 173 54 0.147 0 2 6 48 0.129 8 23 NR 
2 44 0.102 14 8  
6 Supraglottis 12 56 0.145 NA NA 15 43 0.215 3 1 NR 
7 Oropharynx - - - - - 5 38 0.139 7 5 NR 
8 Supraglottis - - - - - 10 35 0.242 2 8 R 
15 41 0.346 1 4  
9 Oropharynx - - - - - 17 45 0.060 1 2 R 
10 Oropharynx 45 56 0.117 1 4 - - - - - R 
Median 28 54 0.135 1 3 5 43 0.186 2 5  
